Dr Alexander Louie, Scientist, and Bev Moir, Lung Cancer Advocate: “Why lung cancer should be on your radar”, January 31, 2023

bev moir
Bev Moir, BScN, MHSc

My career took me from ‘health’ care to ‘wealth’ care, and I loved it! After completing a nursing science degree at Queen’s University and a graduate degree in health administration at the University of Alberta, I spent 20 years in health care, primarily in academic tertiary care settings. During the early 1990s, I sought another opportunity and spent 26 years at Scotia Wealth Management, where I built and led a wealth advisory practice.

In 2019 I was diagnosed with stage 4 non-small cell lung cancer (NSCLC) and given a life expectancy of six months to three years. As the reality hit, it’s not surprising my priorities shifted. By February 1, 2020, I successfully transitioned my practice to another Scotia Wealth advisor to spend my remaining time with family and friends doing what I enjoy.

Recent advances in cancer diagnostics and treatment help more cancer patients live longer and higher quality lives. Biomarker testing, an advanced diagnostic test, identifies patients eligible for therapies that more precisely and effectively target their tumour cells. As a result, patients experience fewer toxic side effects than conventional therapy, such as chemotherapy. As the grateful beneficiary of advanced biomarker testing at Sunnybrook Hospital, I lead an active life and live beyond my ‘best before date.’

Dr. Alexander Louie (please see below) will join me to supplement my patient experience with medical knowledge. I’ll discuss what made me an advocate, our fundraising success and challenges, and the potential of funding to make a difference for those living with lung cancer.

The overriding theme is that anyone with lungs can get lung cancer; it should be on everyone’s radar.

Alexander Louie, MD, PhD, M.Sc., FRCPC Scientist, Sunnybrook Health Sciences Centre


  • PhD cum laude, Lung SABR, Department of Radiation Oncology, VU University, Amsterdam,
  • MSc, Epidemiology, Department of Epidemiology, Harvard School of Public Health
  • MD, Schulich School of Medicine and Dentistry, Western University
  • BSc with distinction, Department of Biology, Western University

Professional Memberships

  • American Society of Clinical Oncology (ASCO)
  • American Society of Radiation Oncology (ASTRO)
  • International Association for the Study of Lung Cancer (IASLC)
  • Canadian Association of Radiation Oncologists (CARO)
  • Ontario Medical Association (OMA)
  • The College of Physicians and Surgeons of Ontario
  • The Royal College of Physicians and Surgeons of Canada

Research Synopsis:
The use of comparative effectiveness in the context of lung, kidney and oligometastatic cancers. Building on his advanced training in Epidemiology (MSc, Harvard School of Public Health) and lung SABR (PhD cum laude, VU University), he is an expert in clinical trial design, cost-effectiveness analyses, Markov modelling, patient-reported outcomes, population-based analyses and appraisal of new technologies. As an avid educator and mentor to many research students, his goal is to motivate his students to take ownership of their projects to answer practical questions within Radiation Oncology.